10-K: Acro Biomedical Reports Continued Losses, Operational Halt

Acro Biomedical Co., Ltd. filed its 2024 annual report, revealing no revenue, significant losses, and substantial doubt about its ability to continue as a going concern.

Summary

• Acro Biomedical Co., Ltd. has not generated any revenue since December 31, 2022, through the date of this annual report.
• The company reported a net loss of $42,297 for the year ended December 31, 2024, and $8,807,573 for the year ended December 31, 2023.
• At December 31, 2024, the company had minimal cash of $476 and a working capital deficiency of $321,870.
• Research and development efforts for a cordyceps-infused chicken feed, which incurred $4,794,825 in expenses in 2023, did not result in a marketable product, and no R&D expenses were incurred in 2024.
• The company's financial statements include a going concern paragraph, indicating substantial doubt about its ability to continue operations.
• The common stock is traded on the OTC Market Group's Expert Market, which means it is not eligible for proprietary broker-dealer quotes and has no published quotes, severely limiting liquidity.
• Management identified material weaknesses in internal controls over financial reporting and disclosure controls due to limited staff and lack of segregation of duties.
• The company relies on advances from a minority stockholder and its chief executive officer for funding, with no assurance of continued support.

Sentiment

Score: 1

Explanation: The company is in severe financial distress, reporting no revenue for two years, minimal cash, and substantial losses. It faces a going concern warning, failed R&D efforts, and significant operational and governance weaknesses. The stock's illiquid market status and dependence on related-party funding underscore an extremely negative outlook.

Positives

• The net loss significantly decreased from $8.8 million in 2023 to $42,297 in 2024, primarily due to the full amortization of deferred stock compensation related to R&D in 2023.
• Advances from a minority stockholder and the CEO continue to provide minimal funding for operations, totaling $36,792 in 2024.
• A lease agreement for a storage facility in Hong Kong was secured until December 2025, indicating some operational continuity, albeit minimal.

Negatives

• No revenue has been generated since December 31, 2022.
• The company incurred a net loss of $42,297 in 2024 and $8,807,573 in 2023.
• Cash balance is critically low at $476 as of December 31, 2024.
• Working capital deficiency worsened to $(321,870) at December 31, 2024, from $(286,949) at December 31, 2023.
• A $480,000 provision for doubtful accounts was recognized in 2023, indicating significant uncollectible receivables from prior sales.
• Research and development efforts for a cordyceps-based chicken feed failed to produce a marketable product, and these efforts have ceased.
• The company's common stock trades on the OTC Market Group's Expert Market, resulting in no active trading market, no market makers, and restricted public viewing of quotations.
• Management concluded that disclosure controls and internal controls over financial reporting were not effective due to limited staff, lack of segregation of duties, and reliance on third-party consultants.
• The company has only one part-time, unpaid employee (the CEO/CFO), who lacks an accounting background, exacerbating control weaknesses.
• The company is delinquent in its SEC filings, with quarterly reports for Q1 2025 not yet filed as of the report date.
• Operations are heavily dependent on related-party funding, with no guarantee of continued support.
• The company does not have product liability insurance, exposing it to significant liabilities from potential claims.
• The market for cordyceps products is highly competitive, with many larger and better-capitalized competitors.
• The business plan is in preliminary stages and requires significant funding, with no assurance of success.
• Past revenue was impaired by political instability in Hong Kong and the aftereffects of China's COVID-19 restrictions on its customer base.

Risks

• Inability to recommence business, generate revenue, or operate profitably.
• Requirement for significant funding with no assurance of availability or favorable terms, potentially leading to significant stockholder dilution.
• Dependence on a minority stockholder and CEO for funding, with no assurance of continued support.
• Failure of past and potential future research and development efforts to yield marketable products.
• Substantial doubt about the company's ability to continue as a going concern.
• Inability to develop a broader customer base and reliance on a small number of customers.
• Revenue impairment due to political instability in Hong Kong and the aftereffects of China's COVID-19 restrictions.
• Adverse effects on business from outbreaks of communicable diseases, natural disasters, or other catastrophic events.
• Exposure to government regulations in the United States and other countries if operations expand, requiring significant compliance costs.
• Potential liability for product purity or adverse reactions, especially without product liability insurance or contractual recourse against suppliers.
• Need to develop additional sources of supply for raw materials and finished products, with risks of shortages, delays, or increased costs.
• Inability to develop and maintain effective marketing and distribution channels.
• Highly competitive market for cordyceps products, with larger and better-capitalized competitors.
• Market for products may be affected by recalls, successful litigation, or changes in public tastes.
• Dependence on CEO Pao-Chi Chu, who works part-time and has potential conflicts of interest with other companies he controls.
• Inability to attract, train, and retain qualified executive, administrative, research and development, marketing, and financial personnel.
• Inability to protect any intellectual property that may be developed.
• Adverse effects on business and gross margin from inflation, global supply chain issues, and increased tariffs.
• Lack of an active trading market for common stock on the OTC Expert Market, making it difficult to buy or sell shares.
• Common stock being a 'penny stock' if a market develops, which may reduce trading activity and make it difficult for investors to sell shares.
• Ineffective disclosure controls and internal controls over financial reporting, potentially leading to undetected material misstatements.
• Lack of a full-time chief financial officer, impairing financial control development and fundraising ability.
• Absence of independent directors, leading to a lack of checks and balances on the CEO.
• Failure to file SEC reports in a timely manner, affecting market perception and potentially leading to SEC action.
• Difficulty for investors to enforce federal securities laws or other legal rights against the sole director/officer located outside the United States.
• Stock price volatility due to low public float and lack of trading volume.
• CEO's significant stock ownership (49.97%) gives him control over corporate actions.
• No intention to pay cash dividends in the foreseeable future.

Future Outlook

The company intends to recommence its operations but cannot provide any assurance of success. It may seek to continue the development of a cordyceps-based chicken feed or other products, but such efforts would require significant funding. There is no assurance that any development efforts will result in a marketable product or that the company will generate revenue or profits in the future. The company anticipates continued inflationary pressures and supply chain disruptions, which may result in delays and increased costs.

Management Comments

• "Our business plan is in the preliminary stages, and we will require significant funding to implement our business plan, with no assurance that we can or will be successful in developing and implementing our business plan."
• "Although we intend to recommence our operations, we cannot give any assurance that we will be successful in these efforts."
• "We have no plans to recommence the development effort for a cordyceps-based chicken feed, although we may seek to recommence this development effort or seek to develop another product."
• "We cannot give any assurance that our chief executive officer or the minority stockholder will continue to fund our operations, and we may not be able to recommence our operations without such funding."

Industry Context

Acro Biomedical operates in the nutritional products market, focusing on cordyceps, a traditional Chinese medicine ingredient. This market is highly competitive, with numerous established companies, many of which are larger and better capitalized. The company's proposed cordyceps-infused chicken feed targets a niche market believed to be relatively small due to the high cost of cordyceps. Historically, the company's sales were concentrated in China and Hong Kong, a region significantly impacted by China's Zero-COVID policy and political instability, which adversely affected customer demand and payment ability.

Comparison to Industry Standards

• Many competitors in the cordyceps market, such as Real Mushrooms, Bulk Supplements, Terrasoul SuperFoods, Mental Refreshment Nutrition, NOW Foods, Aloha Medicinals, Natures Elements, and Swanson Premium, are better known and better capitalized than Acro Biomedical.
• The market for cordyceps in chicken feed is considered relatively small, as cordyceps is an expensive ingredient typically used for human consumption.
• The company's products compete with cheaper, lower-quality cordyceps products available in China, which may affect market acceptance for its higher-quality offerings.

Corporate Governance

Related Party Transactions

• The company owed $1,100 to its chief executive officer, Pao-Chi Chu, for non-interest-bearing advances as of December 31, 2024.
• A minority stockholder advanced $1,000 and paid expenses of $35,792 on behalf of the company during 2024.
• The company owed $124,488 to the minority stockholder for non-interest-bearing advances and expenses paid on its behalf as of December 31, 2024.
• Imputed interest at a rate of 4% on related party advances amounted to $4,339 in 2024 and $3,206 in 2023.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises, suffer from the absence of an active trading market for common stock (OTC Expert Market), and have no expectation of cash dividends. The CEO's controlling ownership limits other stockholders' influence.
• **Employees**: The company has only one part-time, unpaid employee (the CEO/CFO), indicating no current employment opportunities or benefits for a broader workforce. Future hiring is contingent on significant financial improvement.
• **Customers**: Past customers experienced financial losses due to external factors (COVID-19, political instability), leading to uncollectible accounts for the company. There are no current orders, indicating a lack of customer base.
• **Suppliers**: The company has no long-term agreements with suppliers, potentially leading to supply chain instability, higher costs, and difficulty in obtaining necessary products if operations resume.
• **Creditors**: Primarily related parties (CEO and a minority stockholder) who have provided non-interest-bearing advances, indicating a high reliance on internal funding sources with no external credit relationships.

Next Steps

• Intends to recommence operations, though success is not assured.
• May seek to continue development of a cordyceps-based chicken feed or other products.
• May seek to raise funds in the equity market to support operations.
• Plans to implement procedures for segregation of duties if sufficient income allows for hiring additional personnel.
• Expects to adopt a code of ethics as the business develops.

Key Dates

Recommendation

Acro Biomedical is in a critical state, marked by two years of no revenue, minimal cash reserves, and substantial accumulated losses. The company operates under a going concern warning from its auditors, indicating severe financial instability. Its past R&D efforts failed, and there is no clear path to generating revenue or achieving profitability. The stock's trading on the OTC Expert Market renders it highly illiquid and inaccessible to most investors. Fundamental weaknesses in internal controls and corporate governance, coupled with heavy reliance on related-party funding, present insurmountable risks. For any existing holdings, a strong sell is warranted due to the high probability of further value erosion and operational failure. New investment is highly speculative and not advisable.

Keywords

cordyceps, nutritional products, biomedical, SEC filing, 10-K, financial reporting, going concern, OTC Expert Market, stock-based compensation, related party transactions, internal controls, Hong Kong, Taiwan, China, supply chain, inflation, product development, dietary supplements